AzurRx BioPharma Inc (NASDAQ:AZRX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price target of $7.83 for the company and are anticipating that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 94 out of 255 based on the ratings given to related companies.
Separately, HC Wainwright set a $6.00 target price on AzurRx BioPharma and gave the company a “buy” rating in a research report on Friday, June 1st.
Shares of AzurRx BioPharma stock traded up $0.04 on Monday, hitting $2.65. 11,035 shares of the company’s stock traded hands, compared to its average volume of 27,796. AzurRx BioPharma has a one year low of $2.20 and a one year high of $5.25.
Institutional investors have recently made changes to their positions in the stock. Opaleye Management Inc. bought a new stake in shares of AzurRx BioPharma during the 2nd quarter valued at about $417,000. Ardsley Advisory Partners boosted its holdings in AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock worth $440,000 after acquiring an additional 54,697 shares in the last quarter. Parsons Capital Management Inc. RI boosted its holdings in AzurRx BioPharma by 20.3% in the first quarter. Parsons Capital Management Inc. RI now owns 329,515 shares of the company’s stock worth $1,035,000 after acquiring an additional 55,540 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new position in AzurRx BioPharma in the second quarter worth approximately $1,782,000. Institutional investors own 18.61% of the company’s stock.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Read More: How to Invest in Marijuana Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.